- Definition of gavilimomab - NCI Drug Dictionary - NCI
gavilimomab A murine IgM monoclonal antibody (MoAb) developed for the potential treatment of graft versus host disease (GvHD) Gavilimomab recognizes human CD147 antigen, weakly expressed on human leukocytes and up-regulated on activated lymphocytes
- Gavilimomab - Drug Targets, Indications, Patents - Synapse
Gavilimomab: a BSG inhibitors Drug, Initially developed by Abgenix, Inc , Now, its global highest R D status is Discontinued, Mechanism: BSG inhibitors (Basigin inhibitors), Therapeutic Areas: Immune System Diseases,Skin and Musculoskeletal Diseases
- Buy Research Grade Gavilimomab biosimilar
Where to buy Purchase Research Grade Gavilimomab biosimilar for research use? Buy research grade Research Grade Gavilimomab biosimilar on abinscience com, Research Grade Gavilimomab antibody
- gavilimomab - Diccionari dimmunologia | TERMCAT
Note El gavilimomab s'anomena també ABX-CBL El gavilimomab resulta una mica menys eficaç que la teràpia estàndard amb globulina antitimocítica
- Gavilimomab | Abbexa Ltd
This product is for research use only (RUO) by laboratories It is not suitable for use in humans or as a medicine Gavilimomab is a Humanized Monoclonal antibody, expressed in Mammalian cells
- Ozmosi | Gavilimomab Drug Profile
Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living
- Gavilimomab: Uses, Interactions, Mechanism of Action | DrugBank Online
Investigated for use treatment in graft versus host disease Build, train, validate predictive machine-learning models with structured datasets Tap into our Clinical API for life-saving information on contraindications blackbox warnings, population restrictions, harmful risks, more
- Gavilimomab (ABX-CBL) | Anti-CD147 mAb | MedChemExpress
Gavilimomab (ABX-CBL) is an IgM murine monoclonal antibody that recognizes CD147 on the cell surface and initiates cell killing through complement-mediated lysis Gavilimomab can be used for the research of graft-versus-host disease (GVHD)
|